Economic evaluation of high-dose inactivated influenza vaccine in adults aged ≥65 years: A systematic literature review
| Autor: | Fabián P. Alvarez, Edward Thommes, Florian Colrat, Nathalie Largeron |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pediatrics
medicine.medical_specialty Canada Influenza vaccine Cost effectiveness Cost-Benefit Analysis 030231 tropical medicine Population 03 medical and health sciences 0302 clinical medicine Health care Influenza Human Medicine Humans 030212 general & internal medicine education Aged education.field_of_study Health economics General Veterinary General Immunology and Microbiology business.industry Public Health Environmental and Occupational Health Cardiorespiratory fitness Infectious Diseases Systematic review Vaccines Inactivated Influenza Vaccines Economic evaluation Molecular Medicine business |
| Zdroj: | Vaccine. 39 |
| ISSN: | 1873-2518 |
| Popis: | Introduction Due to waning immunity, adults aged ≥65 years are at increased risk of seasonal influenza infection and its complications. Adding to this risk, older adults have reduced responses to influenza vaccines. A high-dose trivalent inactivated influenza vaccine (Fluzone High-Dose, Sanofi Pasteur) (IIV3-HD) was developed to improve protection against influenza in adults aged ≥65 years and has been licensed in the US since 2009 and in Canada since 2015. Post-licensure studies have shown that IIV3-HD is more effective than standard–dose trivalent inactivated influenza vaccine (IIV3-SD) at protecting against influenza infection in this population. Here, we performed a systematic review of economic analyses of IIV3-HD in adults aged ≥65 years. Methods On June 9, 2019, using the Ovid search platform, we searched Econlit, Embase, and Ovid MEDLINE® for original studies published in peer-reviewed journals examining the economics or cost-effectiveness of IIV3-HD in adults aged ≥65 years. Two reviewers independently selected studies and assessed their quality. Results Seven studies were selected, all performed in the US or Canada. Five studies were funded by IIV3-HD manufacturer, and the remaining two by the US National Institute of General Medical Sciences. In all studies, IIV3–HD reduces healthcare resource utilization and is cost-effective or cost-saving compared to IIV3-SD. The main driver is reduced hospitalizations for cardiorespiratory events. Conclusion IIV3-HD is cost-saving or cost-effective versus IIV3-SD in adults aged ≥65 years. Reduced cardiorespiratory complications are an important driver of these economic benefits. A video summary of the article can be accessed via the Supplementary data link at the end of this article. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect